• Published in JMIR (2023)

  • Collaborator: Roche

  • Authors: Pasquale Varriale, Borna Müller, Grégory Katz, Lorraine Dallas, Alfonso Aguaron, Marion Azoulai, Nicolas Girard

While the lung cancer (LC) treatment landscape has rapidly evolved in recent years, easing symptom burden and treatment side effects remain central considerations in disease control. The aim of this study was to assess the relative importance of dimensions of LC care to patients,
and to explore the disease burden, including socioeconomic aspects not commonly covered in patient-reported outcomes instruments.